Results

1–10 of 19 results for Charles C Wykoff

Tarcocimab Tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for DME: First-Time Efficacy, Durability and Safety Results of the GLEAM and GLIMMER Phase 3 studies
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2023
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2024
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2022
Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022
Intravitreal Gene Therapy for Diabetic Macular Edema With ADVM-022: First-Time Data Presentation of Prospective, Randomized Phase 2 INFINITY Trial
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2021
Intravitreal Gene Therapy for Diabetic Macular Edema With ADVM-022: First-Time Data Presentation of Prospective, Randomized Phase 2 INFINITY Trial
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2021
Intravitreal Gene Therapy for Neovascular AMD With ADVM-022: Results of the Phase 1 OPTIC Trial
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2020
Diabetic Retinopathy Part I Take-Home Panel
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2019
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: One-Year Primary Outcomes From the Randomized RECOVERY Trial
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2019